Primary Cutaneous Adenoid Cystic Carcinoma in a Rare Location With an Immune Response to a BNT162b2 Vaccine: A Case Report

JBJS Case Connect. 2024 Apr 12;14(2). doi: 10.2106/JBJS.CC.23.00499. eCollection 2024 Apr 1.


Case: In this report, a rare case of primary cutaneous adenoid cystic carcinoma (PCACC) localized in the subcutaneous tissue of the scapular region that grew after BNT162b2 corona virus disease of 2019 (COVID-19) vaccination is presented and may be explained by CD4 and CD8 cell infiltration. The BNT162b2 mRNA vaccine has been associated with a multisystem inflammatory syndrome (MIS-V). A comparable immune reaction could potentially enhance tumor growth rate.

Conclusion: Primary cutaneous adenoid cystic carcinomas are rare tumors with unique locations. Further studies with case series are required to establish management algorithms for PCACC and investigate the potential effect of vaccination.

Publication types

  • Case Reports

MeSH terms

  • BNT162 Vaccine
  • COVID-19*
  • Carcinoma, Adenoid Cystic*
  • Humans
  • Immunity
  • Vaccination
  • Vaccines*


  • BNT162 Vaccine
  • Vaccines